Cargando…
Prognostic factors and clinical efficacy of second-line treatments of Pneumocystis jirovecii pneumonia for non-HIV patients after first-line treatment failure
BACKGROUND: Pneumocystis jirovecii pneumonia (PCP) is a life-threatening opportunistic infection. In non-HIV immunocompromised patients with PCP, a standard second-line treatment has not been established up to now. METHODS: Non-HIV immunocompromised patients with confirmed PCP between April 2013 and...
Autores principales: | Liu, Anlei, Sun, Ruixue, Cao, Guanghui, Liu, Xiaohang, Zhu, Huadong, Yang, Jing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9199170/ https://www.ncbi.nlm.nih.gov/pubmed/35701759 http://dx.doi.org/10.1186/s12879-022-07523-y |
Ejemplares similares
-
Pneumocystis jirovecii pneumonia in developing countries
por: De Armas Rodríguez, Y., et al.
Publicado: (2011) -
Pneumomediastinum Associated with HIV-positive Pneumocystis jirovecii Pneumonia
por: Hosoda, Tomohiro, et al.
Publicado: (2019) -
Pneumocystis jirovecii pneumonia following everolimus treatment of metastatic breast cancer
por: Kuik, Kelvin Teck-Hong, et al.
Publicado: (2014) -
On the Treatment of Pneumocystis jirovecii Pneumonia: Current Practice Based on Outdated Evidence
por: McDonald, Emily G, et al.
Publicado: (2021) -
Atypical radiographic manifestation in Pneumocystis jirovecii pneumonia
por: Yamakuchi, Hiroki
Publicado: (2017)